Intellia's news comes at a challenging time for gene therapies, as multiple serious adverse events and fatalities have been ...

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme of ESK-001 for treating plaque psoriasis.

Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

Entrada has secured the authorisation within the EU Clinical Trial Regulation to begin the Phase I/II trial of ENTR-601-45.

After Lykos' rejection from the FDA last year, companies trying to navigate the psychedelic drug trial sector face various ...

Pfizer’s and Arvinas’ vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) ER degrader which slows tumour growth.

WCG has launched the WCG Study Accelerator, an integrated solution designed to optimise the clinical trial process.